Biochemistry (Mosc)

1. PCHELINA SN, Bezrukova AI, Rudenok MM, Zhuravlev AS, et al
   The Double Toxic MPTP+CBE Presymptomatic Parkinson-Like Phenotype in Mice.
   Biochemistry (Mosc). 2025;90:1049-1063.
   

   >> Share

   
   

   
   Brain Res

2. CAI L, Ding Y, Tekreeti AA, Li F, et al
   Remote ischemic conditioning as a potential therapy for Parkinson's Disease: Inhibiting TLR4-Driven neuroinflammation and oxidative damage.
   Brain Res. 2025 Sep 1:149920. doi: 10.1016/j.brainres.2025.149920.
   

   >> Share

   
   

   
   J Biol Chem

3. ADHIKARI A, Tripathi A, Chiang CY, Sherpa P, et al
   Allosteric regulation of the Golgi-localized PPM1H phosphatase by Rab GTPases modulates LRRK2 substrate dephosphorylation in Parkinson's disease.
   J Biol Chem. 2025 Sep 3:110679. doi: 10.1016/j.jbc.2025.110679.
   

   >> Share

   
   
4. SAWAI T, Nakamura Y, Arawaka S
   Secretory autophagy mediates lysosomal and autophagic degradation for alpha-synuclein proteostasis.
   J Biol Chem. 2025;301:110474.
   

   >> Share

   
   
5. SHEN L, Zhang J, Wang Z, Liu Y, et al
   Targeted degradation of alpha-synuclein by arginine-based PROTACs.
   J Biol Chem. 2025;301:110449.
   

   >> Share

   
   

   
   J Neural Transm (Vienna)

6. REYES NGD, Pajo AT, Saranza G, Hoglinger GU, et al
   Revisiting Parkinson's disease definition and classification: insights from two emerging biological frameworks.
   J Neural Transm (Vienna). 2025 Sep 4. doi: 10.1007/s00702-025-03013.
   

   >> Share

   
   
7. JENNER P, Nyholm D
   COMT inhibition with entacapone for patients with Parkinson's disease and motor complications: the novelty of continuous infusion.
   J Neural Transm (Vienna). 2025 Sep 2. doi: 10.1007/s00702-025-03006.
   

   >> Share

   
   
8. PELLICANO C, Belvisi D, Bovenzi R, Costanzo M, et al
   Opicapone in Parkinson's disease: a real-world, multicenter, retrospective study to identify patient characteristics for sustained treatment benefit.
   J Neural Transm (Vienna). 2025 Aug 31. doi: 10.1007/s00702-025-03000.
   

   >> Share

   
   

   
   J Neurochem

9. USENKO TS, Basharova KS, Bezrukova AI, Grigor'eva EV, et al
   Restoration of Lysosomal Hydrolase Activities by LRRK2 Inhibition in GBA1- and LRRK2-Associated Parkinson's Disease Patient-Derived Cells.
   J Neurochem. 2025;169:e70214.
   

   >> Share

   
   

   
   Mov Disord

10. FANT A, Trova S, Monfrini E, Treves G, et al
    Compound Heterozygous Structural Variants in Cases with Unsolved PRKN-Associated Parkinson's Disease.
    Mov Disord. 2025 Aug 30. doi: 10.1002/mds.70027.
    

    >> Share

    
    
11. HAQ IU, Simonyan K, Napoli E, Ozelius LJ, et al
    Structural Alterations in the Gray Matter Volume in Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.30320.
    

    >> Share

    
    
12. SCHIESS MC, Suescun J, Martinez-Lemus JD, Green C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.70028.
    

    >> Share

    
    
13. DE MORAES ALVES AL, da Silva Simoes J, Trajano da Silva LR, Neto AF, et al
    Transcutaneous Spinal Magnetic Stimulation Affects Subthalamic Activity in Parkinson's Disease.
    Mov Disord. 2025 Sep 3. doi: 10.1002/mds.70035.
    

    >> Share

    
    
14. AL-AZZANI M, Weber S, Ramalingam N, Ramon M, et al
    A Novel alpha-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease.
    Mov Disord. 2025 Sep 4. doi: 10.1002/mds.70030.
    

    >> Share

    
    

    
    Nat Med

15. ALI M, Erabadda B, Chen Y, Xu Y, et al
    Author Correction: Shared and disease-specific pathways in frontotemporal dementia and Alzheimer's and Parkinson's diseases.
    Nat Med. 2025 Sep 2. doi: 10.1038/s41591-025-03970.
    

    >> Share

    
    

    
    Neurobiol Dis

16. LI P, Zhou X, Luo N, Zhou S, et al
    Dynamic cortical inhibition imbalance as a biomarker of clinical progression in early Parkinson's disease.
    Neurobiol Dis. 2025 Sep 3:107083. doi: 10.1016/j.nbd.2025.107083.
    

    >> Share

    
    
17. BHARTI E, DeNicola AL, Yu Y, Verma AK, et al
    Alterations in beta oscillatory activity occur with the emergence of parkinsonian motor signs across the basal ganglia-thalamocortical network.
    Neurobiol Dis. 2025;215:107075.
    

    >> Share

    
    
18. CHEN T, Gong T, Chen Y, Yang A, et al
    Multimodal MRI biomarkers optimize differentiation between progressive supranuclear palsy and Parkinson's disease.
    Neurobiol Dis. 2025;215:107076.
    

    >> Share

    
    

    
    Neurologia (Engl Ed)

19. MURUETA-GOYENA A, Del Pino R, Carmona-Abellan M, Tijero B, et al
    Effect of sex on the progression of non-motor symptoms in Parkinson's disease: A registry-based cohort study.
    Neurologia (Engl Ed). 2025;40:620-629.
    

    >> Share

    
    

    
    Neurology

20. AITA SL, Roth RM
    Much Ado About Nothing? Midlife Vascular Risk Factors and Incident Parkinson Disease.
    Neurology. 2025;105:e214127.
    

    >> Share

    
    
21. JOHRI M, Morrill V, Okine DN, Huang X, et al
    Midlife Vascular Risk Factors, Parkinson Disease, and Parkinson Disease-Dementia: The ARIC Study.
    Neurology. 2025;105:e213931.
    

    >> Share

    
    

    
    Neuroscience

22. ZHIDAN L, Xianjie L, Shulin S, Qiang J, et al
    TREM2 mediates parkinsonism-like neurodegeneration in carbon disulfide-induced neurotoxicity.
    Neuroscience. 2025;585:50-59.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share